Efficacy of treatment with antipsychotics in patients with psychotic disorder. The value of amino acid profile and neurotrophic proteins.

Completed

• Conditions: psychosis; 10039628; schizophrenia

• Registration Number: NL-OMON31735
• Lead Sponsor: GGZ Groep Noord en Midden-Limburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

age 18-65
psychotic disorder
legal competence
willing to participate

Exclusion Criteria

unable to give informed consent
relevant somatic/neurologic disorder
cytogenetic aberration

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The BPRS will be used as primary outcome measure. Secondary outcome measures<br /><br>are the CGI-S and I. A clinical relevant improvement is defined as a reduction<br /><br>of at least 40% on the BPRS total score..</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>